Dr. David J. Vanderweele, M.D.
Medical Oncology (Medical Oncology Physician)
676 N Saint Clair St Ste 850
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Chicago, Pritzker School of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 537
Licensed in Illinois since 2009, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: University of Chicago, Pritzker School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IL license 036123890 (first issued 2009; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- Northwestern Memorial Hospital Chicago, IL
- Northwestern Lake Forest Hospital Lake Forest, IL
- Palos Community Hospital Palos Heights, IL
- Northwestern Medicine Mchenry Mchenry, IL
Medical groups
- Northwestern Medical Faculty Foundation (4,503 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 537
- Services billed
- 79,008
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 9,180 | 43 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 7,020 | 22 |
| Injection, pembrolizumab, 1 mg | 5,800 | 16 |
| Injection, fosaprepitant, 1 mg | 4,950 | 23 |
| Injection, oxaliplatin, 0.5 mg | 4,102 | 11 |
| Injection, iron sucrose, 1 mg | 2,400 | 12 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 1,870 | 15 |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 1,459 | 18 |
| Injection, atropine sulfate, 0.01 mg | 1,060 | 17 |
| Injection, bortezomib, 0.1 mg | 1,044 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Chicago, IL | 200 |
| Orgovyx (relugolix) | 162 |
| Abiraterone Acetate | 161 |
| Nubeqa (darolutamide) | 74 |
| Xtandi (enzalutamide) | 44 |
| Cabometyx (cabozantinib s-malate) | 36 |
| Gabapentin Other prescribers in Chicago, IL | 28 |
| Tamsulosin Hcl Other prescribers in Chicago, IL | 28 |
| Prochlorperazine Maleate Other prescribers in Chicago, IL | 16 |
| Inlyta (axitinib) | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 14 payments worth $9,645 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $7,575 |
|---|---|
| Pfizer Inc. | $2,070 |
| Consulting Fee | $8,920 |
|---|---|
| Food and Beverage | $443 |
| Travel and Lodging | $282 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Consulting Fee Xofigo · Oncology | $4,326 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Consulting Fee Nubeqa · Oncology | $2,524 |
| Pfizer Inc. Jun 23, 2025 | Consulting Fee XTANDI · ONCOLOGY | $2,070 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $238 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $44.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $9,519 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals Corporation - A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for A…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.